Prognostic significance of nodal involvement region in clinical stage IIIc breast cancer patients who received primary systemic treatment, surgery, and radiotherapy.

[1]  J. Baselga,et al.  Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. , 2014, The Lancet. Oncology.

[2]  H. Kang,et al.  Outcomes of positron emission tomography-staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[3]  R. Dienstmann,et al.  Combined Modality Therapy of Stage IIIC Breast Cancer , 2011, The breast journal.

[4]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  D. Mankoff,et al.  Internal Mammary Nodal Chain Drainage Is a Prognostic Indicator in Axillary Node-Positive Breast Cancer , 2007, Annals of Surgical Oncology.

[6]  J. Ragaz,et al.  Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Cody,et al.  Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. , 2001, Journal of the American College of Surgeons.

[9]  G. Hortobagyi,et al.  Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Posner,et al.  Should internal mammary nodes be sampled in the sentinel lymph node era? , 2000, Annals of Surgical Oncology.

[11]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[12]  N. Cascinelli,et al.  Risk of Internal Mammary Lymph Node Metastases and Its Relevance on Prognosis of Breast Cancer Patients , 1983, Annals of surgery.

[13]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.